ESR1 and breast carcinoma: In addition, ROC analysis for 5-year relapse-free survival on ER+ tamoxifen-treatment breast cancer patients showed an AUC of 0.66 (95% CI: 0.59–0.74; p-value < 0.0001) (Figure 1D).